Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Mismetti

Showing results (91-100 of 180) with videos related to

Pageof 18
Sort By:
Thrombosis and Haemostasis|March 8, 2003
Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trialSilvy Laporte, Sara Quenet, Andréa Buchmüller-Cordier, et al.
Thrombosis Research|December 5, 2020
Opinion and practice survey about the use of prognostic models in acute pulmonary embolismAntoine Elias, Jeannot Schmidt, Abdelouahab Bellou, et al.
British Journal of Clinical Pharmacology|December 6, 2012
A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycinXavier Delavenne, Edouard Ollier, Thierry Basset, et al.
Plos One|March 14, 2014
Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillationJean-Christophe Lega, Laurent Bertoletti, Cyrielle Gremillet, et al.
British Journal of Clinical Pharmacology|November 14, 2018
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Thrombosis and Haemostasis|June 12, 2010
Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practiceXavier Delavenne, Paul Zufferey, Denis Baylot, et al.
Clinical Pharmacology and Therapeutics|December 1, 2018
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial FibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Thrombosis and Haemostasis|November 8, 2008
Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohortCéline Chauleur, Eva Cochery-Nouvellon, Eric Mercier, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 30, 2019
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 21, 2021
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
Pageof 18

Showing results (91-100 of 180) with videos related to

Sort By:
Pageof 18
Thrombosis and Haemostasis|March 8, 2003
Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trialSilvy Laporte, Sara Quenet, Andréa Buchmüller-Cordier, et al.
Thrombosis Research|December 5, 2020
Opinion and practice survey about the use of prognostic models in acute pulmonary embolismAntoine Elias, Jeannot Schmidt, Abdelouahab Bellou, et al.
British Journal of Clinical Pharmacology|December 6, 2012
A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycinXavier Delavenne, Edouard Ollier, Thierry Basset, et al.
Plos One|March 14, 2014
Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillationJean-Christophe Lega, Laurent Bertoletti, Cyrielle Gremillet, et al.
British Journal of Clinical Pharmacology|November 14, 2018
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Thrombosis and Haemostasis|June 12, 2010
Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practiceXavier Delavenne, Paul Zufferey, Denis Baylot, et al.
Clinical Pharmacology and Therapeutics|December 1, 2018
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial FibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Thrombosis and Haemostasis|November 8, 2008
Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohortCéline Chauleur, Eva Cochery-Nouvellon, Eric Mercier, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 30, 2019
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 21, 2021
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
Pageof 18